Among them, the interactions between tumor-suppressive miRNAs (e.g., miR-126) and SLC transporters (e.g., SLC7A5) not only support the concept of targeting critical SLC transporters for the control of diseases (e.g., cancer) (Zhang et al., 2019; Wang et al., 2020) but also develop effective miRNA medications that may act on multiple therapeutic targets including SLC transporters. The gene discussed is SLC7A5; the disease is neoplasm.